Argos Therapeutics, Inc. (NASDAQ:ARGS) Posts Basic Consolidated EPS Of $-3.6559

0

Argos Therapeutics, Inc. (NASDAQ:ARGS)managed to report annual basic consolidated EPS of $-3.6559, which was for the year ended2015-12-31.The company reported basic consolidated EPS of $-3.6559 for the quarter ended 2015-12-31.

EPS from continuing operations

If you look at the performance of the company’s continuing operations, you see that EPS generated from such operations was {EPS_BASIC_CONT_OPER:1541}} for the year ended 2015-12-31. As for the quarter ended 2015-12-31, continuing operations produced EPS of $-0.5671.

EPS contribution from parent

Argos Therapeutics, Inc. (NASDAQ:ARGS) received of $-3.6559 EPS boost from the parent company for the annual period ended

For the year ended 2015-12-31, the parent of Argos Therapeutics, Inc. (NASDAQ:ARGS) contributed EPS of $-3.6559 to the company’s bottom-line. But for the quarter ended 2015-12-31, EPS boost from the parent was cited as $-3.6559.

What About Basic net EPS

The basic net EPS that Argos Therapeutics, Inc. (NASDAQ:ARGS) reported for the year ended 2015-12-31 stood at $-3.66. For the quarter ended 2015-12-31, the company posted basic net EPS of $-3.66.

What About Consolidated Diluted EPS?

Argos Therapeutics, Inc. (NASDAQ:ARGS)’s consolidated diluted EPS for the year ended 2015-12-31 was reported as $-3.6559. For the quarter ended 2015-12-31 the metric was$-3.6559.

Basic diluted EPS

The company managed to register diluted EPS from continuing operation of at $-3.6559 for the yearended 2015-12-31. But diluted EPS from continuing operations for the quarter ended 2015-12-31 came in at $-3.6559.

Net diluted EPS

Net diluted EPS posted by Argos Therapeutics, Inc. (NASDAQ:ARGS) for the year ended 2015-12-31 was $-3.66. On quarterly basis, net diluted EPS for the quarter ended 2015-12-31 was reported as $-3.66.

What portion of diluted EPS came from parent?

For the annual period ended 2015-12-31, the parent company of Argos Therapeutics, Inc. (NASDAQ:ARGS) said that it parent company boosted its diluted EPS by$-3.6559 in the year ended 2015-12-31. For the quarter ended 2015-12-31, the parent company’s contribution to diluted EPS was $-3.6559.

The company reported net basic EPS of $-3.66 for the year ended 2015-12-31 and net basic EPS of $-3.66 for the quarter ended 2015-12-31.

The number of Argos Therapeutics, Inc. (NASDAQ:ARGS)’s basic shares outstanding at the end of the annual period ended 2015-12-31 was 20.457. That compares with 20.457 basic shares outstanding for the quarter ended 2015-12-31.

Argos Therapeutics, Inc. (NASDAQ:ARGS) had 20.457 diluted shares outstanding at the end of the annual period ended 2015-12-31. But for the quarter ended 2015-12-31, diluted outstanding shares were 20.457.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 31 times, 1 visits today)